Cargando…
Sclerotherapy with 3% polidocanol foam: revolutionizing outpatient treatment in patients with haemorrhoidal disease
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927757/ https://www.ncbi.nlm.nih.gov/pubmed/33660166 http://dx.doi.org/10.1007/s13304-021-01008-4 |
| _version_ | 1783659745228357632 |
|---|---|
| author | Gallo, Gaetano Ronconi, Maurizio Trompetto, Mario |
| author_facet | Gallo, Gaetano Ronconi, Maurizio Trompetto, Mario |
| author_sort | Gallo, Gaetano |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7927757 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-79277572021-03-04 Sclerotherapy with 3% polidocanol foam: revolutionizing outpatient treatment in patients with haemorrhoidal disease Gallo, Gaetano Ronconi, Maurizio Trompetto, Mario Updates Surg Letter to the Editor Springer International Publishing 2021-03-03 2021 /pmc/articles/PMC7927757/ /pubmed/33660166 http://dx.doi.org/10.1007/s13304-021-01008-4 Text en © Italian Society of Surgery (SIC) 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Letter to the Editor Gallo, Gaetano Ronconi, Maurizio Trompetto, Mario Sclerotherapy with 3% polidocanol foam: revolutionizing outpatient treatment in patients with haemorrhoidal disease |
| title | Sclerotherapy with 3% polidocanol foam: revolutionizing outpatient treatment in patients with haemorrhoidal disease |
| title_full | Sclerotherapy with 3% polidocanol foam: revolutionizing outpatient treatment in patients with haemorrhoidal disease |
| title_fullStr | Sclerotherapy with 3% polidocanol foam: revolutionizing outpatient treatment in patients with haemorrhoidal disease |
| title_full_unstemmed | Sclerotherapy with 3% polidocanol foam: revolutionizing outpatient treatment in patients with haemorrhoidal disease |
| title_short | Sclerotherapy with 3% polidocanol foam: revolutionizing outpatient treatment in patients with haemorrhoidal disease |
| title_sort | sclerotherapy with 3% polidocanol foam: revolutionizing outpatient treatment in patients with haemorrhoidal disease |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927757/ https://www.ncbi.nlm.nih.gov/pubmed/33660166 http://dx.doi.org/10.1007/s13304-021-01008-4 |
| work_keys_str_mv | AT gallogaetano sclerotherapywith3polidocanolfoamrevolutionizingoutpatienttreatmentinpatientswithhaemorrhoidaldisease AT ronconimaurizio sclerotherapywith3polidocanolfoamrevolutionizingoutpatienttreatmentinpatientswithhaemorrhoidaldisease AT trompettomario sclerotherapywith3polidocanolfoamrevolutionizingoutpatienttreatmentinpatientswithhaemorrhoidaldisease |